Galectin-3BP/MAC-2BP/LGALS3BP Antibody [Unconjugated]

Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line and HepG2 human hepatocellular carcinoma cell line. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Human Galectin-3BP/MAC-2BP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2226) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for Galectin-3BP/MAC-2BP at approximately 75 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Galectin-3BP/MAC-2BP was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Goat Anti-Human Galectin-3BP/MAC-2BP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2226) at 1.7 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Simple Western lane view shows lysates of HeLa human cervical epithelial carcinoma cell line and HepG2 human hepatocellular carcinoma cell line, loaded at 0.2 mg/mL. A specific band was detected for Galectin‑3BP/MAC‑2BP at approximately 115 kDa (as indicated) using 10 µg/mL of Goat Anti-Human Galectin‑3BP/MAC‑2BP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2226) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the12-230 kDa separation system.

• Reactivity: Hu
• Applications: WB, Simple Western, ICC/IF
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

Galectin-3BP/MAC-2BP/LGALS3BP Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Galectin‑3BP/MAC‑2BP
  Val19-Asp585
  Accession # Q08380
• Specificity: Detects human Galectin‑3BP/MAC‑2BP in direct ELISAs and Western blots. In direct ELISAs, less than 20% cross-reactivity with recombinant mouse Galectin‑3BP/MAC‑2BP is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: LGALS3BP
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 1-15 ug/mL
  • Simple Western 10 ug/mL
  • Western Blot 0.2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Galectin-3BP/MAC-2BP/LGALS3BP Antibody [Unconjugated]

• 90K
• Basement membrane autoantigen p105
• BTBD17B
• galectin-3-binding protein
• Galectin3BP
• Galectin-3BP
• L3 antigen
• Lectin galactoside-binding soluble 3-binding protein
• lectin, galactoside-binding, soluble, 3 binding protein
• LGALS3BP
• M2BP
• Mac-2 BP
• Mac-2-binding protein
• MAC2BP
• MAC-2BP
• MAC-2-BP
• serum protein 90K
• Tumor-associated antigen 90K

Background

Galectin-3 binding protein (Galectin-3BP), also known as MAC-2 binding protein (MAC-2BP or M2BP), and the 90 kDa tumor associated antigen (TAA90K or 90K), is a secreted glycoprotein of the scavenger receptor cysteine-rich (SRCR) superfamily (1, 2). Galectin-3BP binds Galectin-3 (formerly MAC-2) with high affinity, but also binds Galectins -1 and -7, several collagen types, fibronectin, beta 1 integrins and nidogen (3, 6, 7). It is widely expressed in all extracellular fluids and in pericellular areas of cell-rich tissues (1-3). The 585 amino acid (aa) human Galectin-3BP contains an 18 aa signal sequence and four definitive domains (4-6). Domain 1 is a group A scavenger receptor domain (4), domain 2 is a BTB/POZ domain that strongly mediates dimerization (5), and domain 3 is an IVR domain, that is also found following the POZ domain in Drosophila kelch protein. Although little is known about domain 4, recombinant domains 3 and 4 reproduce the solid-phase adhesion profile of full-length Galectin-3BP (5, 6). Glycosylation at seven N-linked sites, generates a molecular size of 85-97 kDa (1, 2, 6). Galectin-3BP dimers form linear and ring-shaped oligomers, most commonly decamers and dodecamers (3, 5). In vitro, Galectin-3BP has been shown to stimulate natural killer cells and lymphokine-activated killer cell activity (2). High Galectin-3BP expression has been correlated with tumor aggressiveness in several, but not all, study systems (7). Mature human Galectin-3BP shares 69% aa identity with mouse cyclophilin C-associated protein (CyCAP), which does not appear to bind Galectin-3 (8). Human Galectin-3BP also shares 73%, 67% and 68% aa identity with relatively uncharacterized orthologs in dog, rat and cow, respectively. A human N-terminally truncated sequence that begins within the BTB/POZ domain (aa 196) has been reported.

1. Koths, K. et al. (1993) J. Biol. Chem. 268:14245.
2. Ullrich, A. et al. (1994) J. Biol. Chem. 269:18401.
3. Sasaki, T. et al. (1998) EMBO J. 17:1606.
4. Hohenester, E. et al. (1999) Nat. Struct. Biol. 6:228.
5. Muller, S. A. et al. (1999) J. Mol. Biol. 291:801.
6. Hellstern, S. et al. (2002) J. Biol. Chem. 277:15690.
7. Grassadonia, A. et al. (2004) Glycoconj. J. 19:551.
8. Jalkanen, K. et al. (2001) Eur. J. Immunol. 31:3075.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Galectin-3BP/MAC-2BP/LGALS3BP Antibody (AF2226)(18)

Publications using AF2226

• Yamanaka, T;Araki, K;Yokobori, T;Muranushi, R;Hoshino, K;Hagiwara, K;Gantumur, D;Ishii, N;Tsukagoshi, M;Watanabe, A;Harimoto, N;Masamune, A;Uojima, H;Mizokami, M;Ito, K;Shirabe, K; Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer Cancer science 2024-02-06 [PMID: 38321872] (Immunohistochemistry, Western Blot, Human)
• Kapustin, A;Tsakali, SS;Whitehead, M;Chennell, G;Wu, MY;Molenaar, C;Kutikhin, A;Bogdanov, L;Sinitsky, M;Rubina, K;Clayton, A;Verweij, FJ;Pegtel, DM;Zingaro, S;Lobov, A;Zainullina, B;Owen, D;Parsons, M;Cheney, RE;Warren, D;Humphries, MJ;Iskratsch, T;Holt, M;Shanahan, CM; Extracellular vesicles stimulate smooth muscle cell migration by presenting collagen VI bioRxiv : the preprint server for biology 2023-08-22 [PMID: 37645762] (Western Blot, Human)
• Beatrice Dufrusine, Emily Capone, Sara Ponziani, Rossano Lattanzio, Paola Lanuti, Francesco Giansanti et al. Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma Molecular Oncology 2023-08-01 [PMID: 37195369] (Immunohistochemistry, Human)
• Beatrice Dufrusine, Emily Capone, Sara Ponziani, Rossano Lattanzio, Paola Lanuti, Francesco Giansanti et al. Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma Molecular Oncology 8/1/2023 [PMID: 37195369]
• GF Jang, JS Crabb, B Hu, B Willard, H Kalirai, AD Singh, SE Coupland, JW Crabb Proteomics of Primary Uveal Melanoma: Insights into Metastasis and Protein Biomarkers Cancers, 2021-07-14;13(14):. 2021-07-14 [PMID: 34298739] (Western Blot, Human)
• E Capone, A Lamolinara, F Pastorino, R Gentile, S Ponziani, G Di Vittori, D D'Agostino, S Bibbò, C Rossi, E Piccolo, V Iacobelli, R Lattanzio, V Panella, M Sallese, V De Laurenz, F Giansanti, A Sala, M Iezzi, M Ponzoni, R Ippoliti, S Iacobelli, G Sala Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma Cancers (Basel), 2020-10-15;12(10):. 2020-10-15 [PMID: 33076448] (Western Blot, Human)
• Aysha Ferdoushi, Xiang Li, Nathan Griffin, Sam Faulkner, M. Fairuz B. Jamaluddin, Fangfang Gao et al. Schwann Cell Stimulation of Pancreatic Cancer Cells: A Proteomic Analysis Frontiers in Oncology 8/25/2020 [PMID: 32984024]
• G Dolgormaa, N Harimoto, N Ishii, T Yamanaka, K Hagiwara, M Tsukagoshi, T Igarashi, A Watanabe, N Kubo, K Araki, T Handa, T Yokobori, T Oyama, H Kuwano, K Shirabe Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling Br. J. Cancer, 2020-07-06;0(0):. 2020-07-06 [PMID: 32624579] (IHC, Human)
• T Seki, M Kanagawa, K Kobayashi, H Kowa, N Yahata, K Maruyama, N Iwata, H Inoue, T Toda Galectin 3-binding protein suppresses amyloid-&beta production by modulating &beta-cleavage of amyloid precursor protein J. Biol. Chem., 2020-01-29;295(11):3678-3691. 2020-01-29 [PMID: 31996371] (Western Blot, Human)
• Natalia A. Cherepanova, Sergey V. Venev, John D. Leszyk, Scott A. Shaffer, Reid Gilmore Quantitative glycoproteomics reveals new classes of STT3A- and STT3B-dependent N-glycosylation sites Journal of Cell Biology 8/5/2019 [PMID: 31296534]
• JK Woo, JE Jang, JH Kang, JK Seong, YS Yoon, HC Kim, SJ Lee, SH Oh Lectin, galactoside-binding soluble 3 binding protein promotes 17-N-Allylamino-17-demethoxygeldanamycin resistance through PI3K/Akt pathway in lung cancer cell line Mol. Cancer Ther, 2017-03-23;0(0):. 2017-03-23 [PMID: 28336809] (Western Blot, Human)
• SR Langley, K Willeit, A Didangelos, LP Matic, P Skroblin, J Barallobre, M Lengquist, G Rungger, A Kapustin, L Kedenko, C Molenaar, R Lu, T Barwari, G Suna, X Yin, B Iglseder, B Paulweber, P Willeit, J Shalhoub, G Pasterkamp, AH Davies, C Monaco, U Hedin, CM Shanahan, J Willeit, S Kiechl, M Mayr Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques J. Clin. Invest, 2017-03-20;0(0):. 2017-03-20 [PMID: 28319050] (IHC, Human)
• M2BP inhibits HIV-1 virion production in a vimentin filaments-dependent manner Sci Rep, 2016-09-08;6(0):32736. 2016-09-08 [PMID: 27604950] (Western Blot, Human)
• Sandra Pankow, Casimir Bamberger, Diego Calzolari et al. F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature 11/30/2015 [PMID: 26618866]
• Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J. Virol., 2012-04-11;86(12):6620-31. 2012-04-11 [PMID: 22496229] (Western Blot, Human, Primate - Macaca mulatta (Rhesus Macaque))
• Silverman A, Nakata R, Shimada H, Sposto R, DeClerck Y A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Cancer Res, 2012-03-02;72(9):2228-38. 2012-03-02 [PMID: 22389450] (ICC, Western Blot, Human)
• Shen M, Siu S, Byrd S, Edelmann KH, Patel N, Ketchem RR, Mehlin C, Arnett HA, Hasegawa H Diverse functions of reactive cysteines facilitate unique biosynthetic processes of aggregate-prone interleukin-31. Exp. Cell Res., 2010-12-21;317(7):976-93. 2010-12-21 [PMID: 21182835] (Western Blot, Human)
• Fukaya Y, Shimada H, Wang LC, Zandi E, DeClerck YA Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J. Biol. Chem., 2008-05-01;283(27):18573-81. 2008-05-01 [PMID: 18450743] (Western Blot, Human)

Reviews for Galectin-3BP/MAC-2BP/LGALS3BP Antibody (AF2226) (2)

Average Rating: 4.5

(Based on 2 reviews)

We have 2 reviews tested in 1 species: Human.

reviewed by: Verified Customer WB Human 01/06/2015

Summary

• Application: Western Blot
• Sample Tested: See PMID 22496229
• Species: Human

reviewed by: Verified Customer WB Human 01/06/2015

Summary

• Application: Western Blot
• Sample Tested: See PMID 21182835
• Species: Human

Bioinformatics

• Gene Symbol: LGALS3BP
• Uniprot:
  • Q08380()